PT79819B - Process to prepare dihydropiridazinone derivatives its salts and pharmaceutical compositions and intermediate compounds there with - Google Patents

Process to prepare dihydropiridazinone derivatives its salts and pharmaceutical compositions and intermediate compounds there with

Info

Publication number
PT79819B
PT79819B PT79819A PT7981985A PT79819B PT 79819 B PT79819 B PT 79819B PT 79819 A PT79819 A PT 79819A PT 7981985 A PT7981985 A PT 7981985A PT 79819 B PT79819 B PT 79819B
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
salts
dihydropiridazinone
derivatives
prepare
Prior art date
Application number
PT79819A
Other languages
English (en)
Other versions
PT79819A (en
Inventor
Robert A Slater
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of PT79819A publication Critical patent/PT79819A/pt
Publication of PT79819B publication Critical patent/PT79819B/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
PT79819A 1984-01-13 1985-01-10 Process to prepare dihydropiridazinone derivatives its salts and pharmaceutical compositions and intermediate compounds there with PT79819B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Publications (2)

Publication Number Publication Date
PT79819A PT79819A (en) 1985-02-01
PT79819B true PT79819B (en) 1987-01-07

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
PT79819A PT79819B (en) 1984-01-13 1985-01-10 Process to prepare dihydropiridazinone derivatives its salts and pharmaceutical compositions and intermediate compounds there with

Country Status (31)

Country Link
US (1) US4654342A (pt)
EP (1) EP0150937B1 (pt)
JP (3) JPS60158181A (pt)
KR (1) KR920006781B1 (pt)
CN (1) CN85101722A (pt)
AT (1) ATE37179T1 (pt)
AU (1) AU572252B2 (pt)
CA (2) CA1251209A (pt)
CS (1) CS248731B2 (pt)
DD (1) DD231350A5 (pt)
DE (1) DE3564941D1 (pt)
DK (1) DK162519C (pt)
ES (3) ES8607949A1 (pt)
FI (1) FI850140L (pt)
GB (1) GB8400863D0 (pt)
GR (1) GR850068B (pt)
HU (1) HU193591B (pt)
IE (1) IE57969B1 (pt)
IL (1) IL74031A (pt)
JO (1) JO1351B1 (pt)
MY (1) MY100124A (pt)
NO (1) NO850129L (pt)
NZ (1) NZ210816A (pt)
PH (1) PH22136A (pt)
PL (1) PL147123B1 (pt)
PT (1) PT79819B (pt)
RO (1) RO92607A (pt)
SU (1) SU1396963A3 (pt)
WO (1) WO1985003076A1 (pt)
ZA (1) ZA85251B (pt)
ZW (1) ZW385A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
ES2271247T3 (es) * 2001-02-27 2007-04-16 Migenix Corp. Aril-n-cianoguanidinas y metodo relacionados con ellas.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
EP1951227B1 (en) * 2005-11-14 2017-04-12 Boehringer Ingelheim Vetmedica GmbH Use of pimobendan for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8664252B2 (en) 2008-11-25 2014-03-04 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
MX2016000727A (es) 2013-07-19 2016-04-13 Boehringer Ingelheim Vetmed Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante.
CN105979959B (zh) 2013-08-09 2021-11-30 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
HUE056143T2 (hu) 2013-12-04 2024-01-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendán javított gyógyászati készítményei
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
EP0059688B1 (de) * 1981-03-04 1985-05-15 Ciba-Geigy Ag Pyridazinone, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen und deren Verwendung
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants

Also Published As

Publication number Publication date
PH22136A (en) 1988-06-01
JPS60158181A (ja) 1985-08-19
EP0150937B1 (en) 1988-09-14
DK9185D0 (da) 1985-01-08
AU3761185A (en) 1985-07-18
IL74031A (en) 1988-07-31
ES8706645A1 (es) 1987-07-01
NO850129L (no) 1985-07-15
WO1985003076A1 (en) 1985-07-18
ES549629A0 (es) 1987-03-01
MY100124A (en) 1989-12-18
DK162519C (da) 1992-03-30
GR850068B (pt) 1985-05-03
ZW385A1 (en) 1985-08-07
HU193591B (en) 1987-11-30
CA1260471C (pt) 1989-09-26
ZA85251B (en) 1986-08-27
JPS63313776A (ja) 1988-12-21
RO92607A (ro) 1987-11-30
AU572252B2 (en) 1988-05-05
ES8607949A1 (es) 1986-06-01
EP0150937A3 (en) 1985-08-21
EP0150937A2 (en) 1985-08-07
KR850005417A (ko) 1985-08-26
SU1396963A3 (ru) 1988-05-15
IE57969B1 (en) 1993-06-02
IE850069L (en) 1985-07-13
DD231350A5 (de) 1985-12-24
NZ210816A (en) 1987-06-30
CA1260471A (en) 1989-09-26
FI850140A0 (fi) 1985-01-11
FI850140L (fi) 1985-07-14
JPS63313775A (ja) 1988-12-21
PT79819A (en) 1985-02-01
US4654342A (en) 1987-03-31
JO1351B1 (en) 1986-11-30
CN85101722A (zh) 1987-01-31
ES539446A0 (es) 1986-06-01
CS248731B2 (en) 1987-02-12
IL74031A0 (en) 1985-04-30
HUT37128A (en) 1985-11-28
PL251516A1 (en) 1985-12-17
ES8703846A1 (es) 1987-03-01
GB8400863D0 (en) 1984-02-15
DK162519B (da) 1991-11-11
PL147123B1 (en) 1989-04-29
KR920006781B1 (ko) 1992-08-17
DK9185A (da) 1985-07-14
ES554965A0 (es) 1987-07-01
DE3564941D1 (en) 1988-10-20
ATE37179T1 (de) 1988-09-15
CA1251209A (en) 1989-03-14

Similar Documents

Publication Publication Date Title
PT79819B (en) Process to prepare dihydropiridazinone derivatives its salts and pharmaceutical compositions and intermediate compounds there with
AU580963B2 (en) New compounds derived from diphenyl-methylene-ethylamine
ES8606330A1 (es) Procedimiento para preparar derivados de acidos quinolincar-boxilicos
ZA842423B (en) Compounds with antiinflammatory activity,process for preparation thereof and pharmaceutical compositions therefrom
ZA872925B (en) Heterocyclic compounds
FR2626279B1 (fr) Nouveaux derives de l'indolo(3,2,1-de)(1,4)-oxazino(2,3,4-ij)(1,5) naphthyridine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
ES8507524A1 (es) Un procedimiento para preparar derivados de tropona
IL79280A (en) 4-(6-oxo-dihydro or tetrahydropyridazin-3-yl)benzene derivatives,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19940731